Compare Ascendis Pharma A/S (ASND) vs Linde PLC (LIN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Linde PLC — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Linde PLC trades at $531.24 (market cap $244.95B). The key difference: Linde PLC is far larger — about 13.8× Ascendis Pharma A/S's market cap, and Linde PLC pays a 1.21% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | LIN | |
|---|---|---|
Market Cap | $17.74B | $244.95B |
Sector | Health | Basic Materials |
52-Week High | $277.18 | $546.64 |
52-Week Low | $163.32 | $389.38 |
Enterprise Value | $18.11B | $267.30B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Linde PLC (LIN) trades at $529.79, up 0.8% today, with strong analyst support (24 buy, 4 hold) and a consensus price target of $560. The stock shows consistent earnings beats, with Q1 2026 EPS of $4.33 exceeding estimates, and robust fundamentals including a 20.44% net margin and 18.49% ROE. Technical indicators are bullish overall, with the current price near resistance at $529.
Outlook remains positive due to steady revenue growth, high profitability, and shareholder returns via dividends. Risks include elevated valuation multiples (P/E 35.13) and rising debt-to-asset ratio. The stock offers a balanced opportunity for growth investors, supported by strong institutional sentiment and operational execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →
